Does Cediranib Prevent Bowel Perforation in Platinum-resistant Ovarian Cancer

Summary

Ovarian cancer can often grow and cause obstructions in the bowel. These obstructions usually cannot be removed with surgery and can be fatal. This trial is testing whether a drug called cediranib can be used safely together with paclitaxel chemotherapy to treat ovarian cancer in women at risk of bowel obstructions. All participants will receive the cediranib/paclitaxel combination, and if the cancer worsens the participant will stop receiving paclitaxel and may receive an additional drug, olaparib, together with cediranib.

Timeline

Start

2018-05-14

Primary completion

2025-01-14

Completion

2025-01-14

Drugs

Indications